Optasia

Optasia Medical is the leading global health technology company focused on next-generation solutions for osteoporosis management.  Optasia’s integrated solutions enable new models of care and dramatic improvement in patient identification, end-to-end care path management, and patient engagement.  Osteoporosis is a common bone disease that results in fragility fractures and affects 1-in-3 women and 1-in-5 men over the age of 50.  With a rapidly ageing population, Singapore’s fragility fracture incidence is expected to increase 58% by 2035, leading to care costs of S$289.6 Million without targeted intervention.

Vertebral fractures are powerful predictors of future fragility fractures but up to 70% go undiagnosed.  Optasia’s leading product, Aspire, is an AI-based CT image-analysis solution that assists radiologists in identification and reporting of vertebral fractures allowing them to focus on the primary diagnosis.  Our Optimal care management platform provides essential tools significantly improving efficiency and effectiveness in managing patients throughout the care pathway.  The MyBoneHealth patient app is directly connected with Optimal, providing a fit-for-purpose environment for developing long-term relationships between providers and patients helping them maintain care plan activity while tracking exercise, nutrition and medication adherence.  All three Optasia solutions are designed to be used independently or as a fully integrated solution operating from a single patient database.   

Specializing in a disease that affects the ageing population, Optasia is keen to assist care providers in Singapore. The healthy ageing mission provides the platform for us to showcase our solutions to the relevant stakeholders and the opportunity to understand the healthcare environment and implementation requirements.